News and Events

India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration

In October 2023, India’s counterpart to the US Food and Drug Administration, the Central Drugs Standard Control Organization, approved NexCAR19, an effective, low-cost CAR-T cell therapy. The development of the therapy was made possible by a years-long collaborative journey between the Indian Institute of Technology Bombay and Tata Memorial Centre in Mumbai with NCI researchers at the NIH Clinical Center. As India’s first approved CAR-T cell therapy, the treatment will be manufactured in Mumbai and is affordable for many.

Clinical trial researching therapy for RUNX1 mutations

A clinical trial led by Lea C. Cunningham, M.D., Associate Research Physician in the Immune Deficiency Cellular Therapy Program, is researching a drug for RUNX1 mutations.

An image of mouse colon tissue (blue), proliferating stem cells (green) and PEDF (red). Image credit: Girak Kim, et al.

The liver controls intestinal health through the PEDF protein

A new study reveals how the liver and gut communicate to regulate stem cell expansion in the repair of damaged intestinal tissue. The finding, from the lab of Chuan Wu, M.D., Ph.D., has important implications for a lipid-lowering drug that affects that communication.

Howard A. Young, Ph.D., cutting the ribbon to celebrate the opening of his lab in the 1980s.

Celebrating CCR Careers: Howard A. Young, Ph.D.

Howard A. Young, Ph.D., spent over 40 years researching cytokine gene expression, especially interferons and how they contribute to chronic inflammation and disease. Now, he has announced his retirement.

Clinical trial researching neuroendocrine neoplasms

A clinical trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is researching the biology of neuroendocrine neoplasms.

Clinical trial researching therapy for neuroendocrine cancer

A clinical trial led by Jaydira Del Rivero, M.D., Associate Research Physician in the Developmental Therapeutics Branch, is researching a combination drug therapy for neuroendocrine cancer.

Celebrating CCR Careers: William G. Stetler-Stevenson, M.D., Ph.D.

For over three decades, William G. Stetler-Stevenson, M.D., Ph.D., has been a leader in the field of tissue inhibitors of metalloproteinases (TIMP) biology and extracellular matrix regulation of cancer.

Celebrating CCR Careers: Allan M. Weissman, M.D.

Allan M. Weissman, M.D., who explored the essential underpinning of ubiquitin in cancer, announces his retirement from the NCI.

Celebrating CCR Careers: Kathleen Kelly, Ph.D.

Kathleen Kelly, Ph.D., who pioneered new frameworks for modeling and exploring how prostate cancer cells respond to anti-cancer drugs, announces her retirement from the NCI.

PROTACtion against resistance of commonly used anti-cancer drug

Drugs known as PIM kinase inhibitors are used to treat a range of cancers, but many patients develop resistance to these medications. Recent research has led to a new class of therapeutics that target the mechanism of this resistance, resulting in increased death of cancer cells.

Breadcrumb